Abbott’s Libre CGM Improves HbA1c and Time-in-Range in FreeDM2 Trial

Abbott has reported results from the FreeDM2 randomized controlled trial (NCT05944432) demonstrating that real-time continuous glucose monitoring (CGM) using the FreeStyle Libre system significantly improved glucose control in people with Type 2 diabetes treated with basal insulin. The findings were presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).

The trial enrolled 303 participants across 24 clinical sites in the United Kingdom and compared continuous glucose monitoring with traditional self-monitoring of blood glucose (SMBG) using finger-stick testing. After four months, participants using the FreeStyle Libre CGM system achieved significantly greater reductions in HbA1c levels than those relying on standard finger-stick monitoring. The CGM group recorded an average HbA1c reduction of 0.6% (p<0.001) and spent around 2.5 additional hours per day within the recommended glucose range of 70–180 mg/dL.

Participants in the study were receiving basal insulin therapy along with modern glucose-lowering medicines such as SGLT2 inhibitors or GLP-1 receptor agonists. Despite these advanced treatments, the addition of real-time glucose monitoring enabled individuals to make informed adjustments to their diet, insulin dosing and physical activity, leading to better glucose outcomes through self-management.

Study investigators emphasized that continuous access to glucose data empowers people with Type 2 diabetes to actively manage their condition. Researchers noted that even patients already receiving advanced therapies experienced meaningful improvements when they could view their glucose levels in real time and respond accordingly throughout the day.

Additional support for the findings came from a separate interventional study conducted in Italy involving 88 adults with Type 2 diabetes using basal insulin in routine clinical practice. After three months of using the FreeStyle Libre system, participants showed improved average glucose levels, spent more time within the healthy glucose range and reported better quality of life.

According to Abbott’s diabetes care leadership, consistent results across both studies highlight the importance of continuous access to glucose information. The ability to monitor glucose patterns in real time helps patients make small but timely adjustments to their daily habits, which can collectively lead to better diabetes control.

Researchers believe the findings strengthen the case for expanding access and reimbursement for CGM technologies, particularly for people with Type 2 diabetes treated with basal insulin. In many healthcare systems, coverage for CGM is still largely limited to patients who require multiple daily insulin injections.

Abbott introduced the Libre continuous glucose monitoring portfolio more than a decade ago. Today, the technology is used by approximately eight million people across more than 60 countries, providing real-time glucose insights that help individuals understand how food, activity and insulin influence their blood sugar levels.

Reference

Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management, 12 March 2026, Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

 CGM Use in Adults with Type 2 Diabetes on Basal Insulin, ClinicalTrials.gov ID NCT05944432, https://clinicaltrials.gov/study/NCT05944432